FDA-Approved Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) Inhibitors for Managing Rheumatoid Arthritis: A Narrative Review of the Literature

FDA-Approved Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) Inhibitors for Managing Rheumatoid Arthritis: A Narrative Review of the Literature

Rheumatoid arthritis (RA) is a complex autoimmune disease causing chronic joint inflammation and, in more serious cases, organ involvement. RA typically affects people between the ages of 35 and 60; however, it can also afflict children younger than the age of 16 years and can also demonstrate a pat...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) Vol. 16; no. 5; p. e59978
Main Authors: Potlabathini, Tejaswini, Pothacamuri, Mounica A, Bandi, Venkata Varshitha, Anjum, Mahnoor, Shah, Parmendra, Molina, M, Dutta, Nilashis, Adzhymuratov, Oleksandr, Mathew, Midhun, Sadu, Vatsalya, Zahid, Shiza A, Lingamgunta, Harini, Sahotra, Monika, Nasiri, Syed Muhammad Zain Jamil, Daguipa, Christine Dawn M
Format: Journal Article
Language:English
Published: United States Cureus Inc 09-05-2024
Cureus
Subjects:
Cytokines
Dermatitis
Disease
FDA approval
Growth factors
Inflammation
Internal Medicine
Kinases
Medical Education
Patients
Phosphorylation
Remission (Medicine)
Rheumatoid arthritis
Rheumatology
Tumors
Japan
rheumatoid arthriitis
teratogenic
cost effective
janus kinase (jak) inhibitors
clinical efficacy
fda-approved medications
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rheumatoid arthritis (RA) is a complex autoimmune disease causing chronic joint inflammation and, in more serious cases, organ involvement. RA typically affects people between the ages of 35 and 60; however, it can also afflict children younger than the age of 16 years and can also demonstrate a pattern of remission later in the disease course. Non-steroidal anti-inflammatory drugs, glucocorticoids, exercise, and patient education are all used in the management of RA, which is divided into symptomatic management and disease-modifying management (disease-modifying antirheumatic drugs) to reduce pain and inflammation, thereby preserving joint function. Janus kinase inhibitors (JAKis) have led to a substantial improvement in the management of RA. By specifically targeting the JAK-signal transducer and activator of transcription pathway, which is essential for immunological modulation, these inhibitors also demonstrate promise in treating various autoimmune illnesses, including inflammatory bowel diseases, giant cell arteritis, ankylosing spondylitis, and psoriatic arthritis. Tofacitinib, baricitinib, upadacitinib, peficitinib, delgocitinib, and filgotinib are examples of FDA-approved JAKis that have distinct properties and indications for treating a range of autoimmune illnesses. JAKis demonstrate a promising treatment approach for managing RA and other autoimmune diseases while enhancing patient outcomes and quality of life. However, due to major safety concerns and the need for long-term success, meticulous patient monitoring is essential.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.59978